The aim of this review is to provide an update on important recent advances in radiologic colorectal imaging, with emphasis on detection, staging, and surveillance of colorectal neoplasia.
INTRODUCTION
Advanced medical imaging techniques play a major role in the clinical management of most organ systems, and the large intestine is no exception. In fact, the progress made in cross-sectional and functional colorectal imaging has greatly accelerated over the past decade. Over the past year or so, the contributions of magnetic resonance (MR), computed tomography colonography (CTC), and positron emission tomography (PET) have been especially noteworthy in terms of advancing the areas of detection, staging, and surveillance of colorectal neoplasia. This review will focus upon the recent advances associated with these imaging modalities.
RECENT ADVANCES IN RECTAL MRI
The utility of MR for the initial staging of rectal cancer has been firmly established for some time now. Local staging of rectal cancer with MR that combines assessment of the primary tumor, regional lymph nodes, and the circumferential resection margin (CRM) allows for the identification of high-risk cohorts that will likely benefit from neoadjuvant chemoradiation therapy. More recently, there has been growing interest in the use of MR for restaging of rectal cancer after preoperative treatment, as up to 25% of patients may achieve a pathological complete response (pCR) with current regimens [1] . Going forward, the identification of complete responders versus nonresponders to neoadjuvant therapy will likely continue to grow in importance as nonoperative management paradigms evolve.
Restaging of rectal cancer with MR, however, is proving to be much more challenging than initial staging, due in part to posttreatment fibrosis and reaction, with mixed results to date. ]. Ferumoxytol is an approved agent for iron replacement in anemia that has both T1 and T2 Ã -shortening properties that can be exploited at MR (off-label use) for both dynamic and delayed imaging [12] . This ultrasmall superparamagnetic iron oxide particle is taken up by the reticuloendothelial system, allowing for differentiation of normal versus abnormal lymph nodes. Initial results in terms of nodal staging with MR are expected within the next year or so.
RECENT ADVANCES IN COMPUTED TOMOGRAPHY COLONOGRAPHY
Within the past year, a number of important studies have been published that further validate the use of CTC as both a diagnostic and screening tool. Most vital, perhaps, were the dual publications of the SIGGAR trial results in the Lancet [13 && ,14 && ]. This UK multicenter study actually consisted of two parallel randomized controlled trials focused on the investigation of symptoms suggestive of colorectal cancer. One study compared CTC with optical colonoscopy [13 && ], whereas the other compared CTC with barium enema [14 && ], both randomized in a ratio of 1 CTC to 2 of the other test. In the CTC (n ¼ 533) versus colonoscopy (n ¼ 1047) arm, detection rates for colorectal cancer and large polyps (!10 mm) were equivalent at 11%. In the CTC (n ¼ 1277) versus barium enema (n ¼ 2527) arm, CTC was significantly more sensitive for detecting large polyps and cancer. Together, these studies validate the use of diagnostic CTC for suspected colorectal cancer as the preferred radiological test, providing a less-invasive alternative to colonoscopy.
In the realm of screening, appropriate management of small (6-9 mm) colorectal polyps detected by CTC has long been an area of controversy, largely because of the perceived dearth of natural history data. We recently reported the results of an 8-year prospective longitudinal trial investigating the in-vivo volumetric growth rates of 6-9 mm polyps detected and followed by CTC [15 && ]. A total of 306 small polyps were followed with a mean surveillance interval of 2.3 years. A 20% change in polyp volume per year was used to categorize lesions according to progression, stability, and regression. Progression was seen in 22% (68 of 306), 50% were stable (153 of 306), and 28% regressed (85 of 306), including KEY POINTS Progress in rectal MRI over the past year was most notable in terms of assessment of cancer response to neoadjuvant therapy to guide management.
Progress in CTC over the past year has included further clinical validation for detection of advanced neoplasia, in-vivo surveillance of small colorectal polyps, and overall maturation of the technique.
Progress in functional PET imaging for colorectal cancer over the past year has included multimodality incorporation of both CT and MR techniques, as well as novel tracers that are more cancer selective.
complete resolution in 10% (32 of 306). Of histologically proven advanced adenomas, 91% progressed (21 of 23), compared with 37% of nonadvanced adenomas and 8% of all other polyps (P < 0.0001). Mean polyp volume increased 77% per year for advanced adenomas, compared with a 16% increase for nonadvanced adenomas, and a 13% decrease for nonneoplastic or unresected polyps (P < 0.0001). We concluded that volumetric growth assessment of small colorectal polyps was a useful biomarker for determination of clinical importance, which could allow for less-invasive surveillance strategies and reserve polypectomy for lesions that show substantial growth.
Flat (nonpolypoid) lesions continue to be an area of active interest within colorectal cancer screening. For a given size, flat lesions are much less conspicuous than their polypoid and pedunculated counterparts at both CTC and colonoscopy, leading to potential missed lesions. In addition, elucidation of the serrated polyp pathway to cancer has also heightened awareness for flat right-sided lesions. Although a number of prior publications have demonstrated the ability of CTC to detect nonpolypoid lesions, Kim et al. [16 & ] recently described the utility of contrast coating along the lesional surface as a marker for detection. This etching of contrast was seen in nearly 80% of 160 flat lesions (mean size, 9.4 mm) at CTC. Large size, proximal colonic location, and serrated histology were all associated with a higher frequency of contrast coating, which serves as a beacon for detection at CTC. A separate recent CTC study described the clinical, imaging, and pathologic features of carpet lesions, which are laterally spreading flat masses measuring 3 cm or larger across [17] . Of the 18 proven carpet lesions, all demonstrated surface coating of contrast and all but two were located in the distal rectosigmoid or proximal right colon. Despite the large size (mean, 4.7 cm), most were histologically advanced adenomas but still benign. Together, these two studies provide further evidence of CTC's ability to detect clinically relevant flat colorectal lesions.
A number of other CTC studies have advanced our knowledge in terms of interpretation and clinical implementation. Pooler et al. [18 & ] showed that variation in the detection of adenomas and advanced neoplasia among radiologists in one CTC screening programme was considerably less than that previously reported for colonoscopy. Pooler ] also provided benchmark screening values for the detection of relevant colorectal and extracolonic findings according to the established CTC reporting and data system (C-RADS), which can be used for comparison by other screening programmes. Lung et al. [20] reported their 5-year experience with CTC in a high-risk population, demonstrating a high PPV for polyps (92%) and high NPV for cancer (99.9%). Of note, PPV for small polyps significantly improved after the introduction of fecal contrast tagging. Pickhardt and Kim [21] reviewed interpretive pitfalls and missed lesions [22] at CTC, drawing from their experience with population screening. Flor et al. [23] proposed a diverticular disease severity score based on findings at CTC, which represents an ideal tool for noninvasive evaluation of this common abnormality. In two separate studies, Flor et al. [24 & ,25 & ] also assessed the utility of CTC for preoperative surgical planning in patients with occlusive colorectal cancer and for preoperative distinction between T1-T2 and T3-T4 cancers. The information obtained from CTC changed that surgical approach in a number of cases. These combined works by Flor et al. [23,24 & 
,25
& ] may ultimately lead to increased utilization of preoperative CTC for both benign and malignant surgical conditions.
RECENT ADVANCES IN PET
PET imaging provides functional information that is complementary to anatomic cross-sectional imaging. As such, multimodality imaging that incorporates PET is gaining significant traction, especially for oncologic investigation. 18 It has been recognized for many years that incidental colorectal adenomas and cancers may be FDG avid on PET studies, leading some to wonder about its potential screening role. However ] emphasize the fact that although incidental PET detection of colorectal neoplasia may lead to early detection in many cases, significant tumors will still be missed if used for screen detection. Cost implications would also preclude the use of PET/CT for asymptomatic screening.
The combination of PET and MR offers the prospect of functional imaging with improved anatomic soft tissue contrast resolution. Despite the substantial technical and economic hurdles encountered with the introduction of PET/MR, the early clinical results are encouraging [31] [32] [33] . Combining stateof-the-art rectal MR, as described above, with FDG PET offers the potential for improved staging, restaging, and surveillance of rectal cancer. Data are expected to surface in the near future.
Although FDG remains the workhorse PET agent for oncologic imaging, it has issues of both decreased specificity (e.g., inflammatory lesions) and sensitivity (e.g., mucinous tumors). Newer PET agents that are more cancer specific may one day replace FDG for oncologic imaging, including colorectal cancer. For example, Weichert et al. [34 && ] recently reported a novel PET tracer ( 124 I-CLR1404) that is highly selective for cancer, demonstrating prolonged uptake in a broad spectrum of human malignancies, although not being retained within benign or inflammatory lesions. Furthermore, this agent can serve as a therapeutic by replacing the 124 I label with 131 I. Preliminary investigations underway in humans appear to confirm the earlier animal studies [35] .
CONCLUSION
In summary, recent advances in cross-sectional and functional radiologic imaging hold enormous potential for transforming the clinical evaluation and management of colorectal neoplasia.
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